Oppenheimer & Co. Inc. acquired a new stake in shares of Amedisys Inc (NASDAQ:AMED) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,908 shares of the health services provider’s stock, valued at approximately $232,000.

Several other large investors also recently made changes to their positions in AMED. Alpha Quant Advisors LLC lifted its position in shares of Amedisys by 137.0% during the 1st quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock valued at $29,000 after acquiring an additional 137 shares during the last quarter. CWM LLC lifted its position in shares of Amedisys by 482.2% during the 2nd quarter. CWM LLC now owns 262 shares of the health services provider’s stock valued at $32,000 after acquiring an additional 217 shares during the last quarter. Tompkins Financial Corp acquired a new stake in shares of Amedisys during the 2nd quarter valued at $37,000. Parkside Financial Bank & Trust acquired a new stake in shares of Amedisys during the 2nd quarter valued at $80,000. Finally, NEXT Financial Group Inc acquired a new stake in shares of Amedisys during the 2nd quarter valued at $82,000. Institutional investors own 89.28% of the company’s stock.

In other news, insider Michael Paul North sold 10,067 shares of the company’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $130.00, for a total value of $1,308,710.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Christopher Gerard sold 350 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $134.79, for a total transaction of $47,176.50. Following the completion of the transaction, the chief operating officer now directly owns 25,381 shares in the company, valued at $3,421,104.99. The disclosure for this sale can be found here. Insiders sold 22,749 shares of company stock worth $2,986,811 over the last ninety days. 2.90% of the stock is currently owned by company insiders.

NASDAQ:AMED traded up $0.66 during trading hours on Friday, hitting $132.31. 3,944 shares of the stock traded hands, compared to its average volume of 199,167. The firm has a 50 day moving average price of $132.82 and a 200 day moving average price of $123.53. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 0.58. Amedisys Inc has a fifty-two week low of $97.38 and a fifty-two week high of $141.98. The firm has a market cap of $4.30 billion, a price-to-earnings ratio of 36.45, a PEG ratio of 2.00 and a beta of 1.46.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 31st. The health services provider reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.24. Amedisys had a net margin of 6.84% and a return on equity of 27.23%. The company had revenue of $492.98 million for the quarter, compared to the consensus estimate of $489.66 million. During the same period in the previous year, the business earned $1.00 EPS. The company’s revenue was up 19.8% on a year-over-year basis. Research analysts predict that Amedisys Inc will post 4.11 EPS for the current year.

A number of brokerages have recently commented on AMED. Jefferies Financial Group set a $150.00 price objective on Amedisys and gave the company a “buy” rating in a research report on Monday, July 8th. BidaskClub upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 26th. Barclays increased their price objective on Amedisys from $120.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 5th. ValuEngine raised shares of Amedisys from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. Finally, Raymond James boosted their target price on shares of Amedisys from $140.00 to $144.00 and gave the company an “outperform” rating in a research note on Monday, July 15th. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $135.90.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Story: What is the definition of a trade war?

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.